Enterprise Therapeutics
Respiratory diseases drugs manufacturer
Total raised
€30M
€30,376,600
Funding rounds
2
Investors
7
distinct backers
Active since
2017-04
latest 2024-01
Funding by year
EUR raised per yearSignals
Medium confidenceRaise-next likelihood53
base rate 48% for Series B
- ▲ In typical raise window
- ▼ Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ €30M+ raised
- ▲ 9y since founding
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-01-30 | Series B | €30M | Epidarex Capital,Forbion,IP Group,Novartis Venture Fund,Panakes Partners,Versant Ventures | View deal → |
| 2017-04-05 | Other | €0 | Cystic fibrosis Trust | View deal → |